NDA 214373 · Theracosbio
Brenzavvy
Bexagliflozin · Oral · Sodium-Glucose Cotransporter 2 Inhibitor
NovelCDER novel approval, Jan 20, 2023: To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Jan 20, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
20
7 Phase 3, 2 recruiting
FAERS reports
31
12 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 30, 2026.
Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. [see Warnings and Precautions ( 5.1 )] . Bexagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitation of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. ( 1 )
Mechanism: Bexagliflozin is an inhibitor of sodium-glucose co-transporter 2 (SGLT2), the transporter responsible for reabsorption of the majority of glucose from the renal glomerular filtrate in the renal proximal tubule. By inhibiting SGLT2, bexagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BRENZAVVY · BEXAGLIFLOZIN 20MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bexagliflozin" as an intervention, any sponsor and status, largest first.
- Bexagliflozin Efficacy and Safety TrialPivotal-lookingCompleted
TheracosIndustry
NCT02558296 · 1,700 participants · Start Oct 2015 · Primary completion Aug 2018
Drug: Bexagliflozin; Placebo · For: Type 2 Diabetes Mellitus
Sites: Gilbert, Arizona; Little Rock, Arkansas; Azusa, California · 157 sites in all
- An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential HypertensionPivotal-lookingCompleted
TheracosIndustry
NCT03514641 · 673 participants · Start Oct 18, 2017 · Primary completion Nov 30, 2018
Drug: Bexagliflozin; Placebo · For: Essential Hypertension
Sites: Birmingham, Alabama; Foley, Alabama; Gulf Shores, Alabama · 87 sites in all
- Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsPivotal-lookingCompleted
TheracosIndustry
NCT02769481 · 426 participants · Start Aug 15, 2016 · Primary completion Jun 14, 2019
Drug: Bexagliflozin; Placebo for Bexagliflozin and 2 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Huntington Park, California; Los Angeles, California · 45 sites in all
- Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsPivotal-lookingCompleted
TheracosIndustry
NCT03115112 · 386 participants · Start Oct 12, 2017 · Primary completion Oct 31, 2018
Drug: Bexagliflozin; Sitagliptin and 2 more · For: Type 2 Diabetes Mellitus
Sites: Lincoln, California; Long Beach, California; San Dimas, California · 56 sites in all
- Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes SubjectsPivotal-lookingCompleted
TheracosIndustry
NCT03259789 · 351 participants · Start Nov 28, 2017 · Primary completion Jan 23, 2019
Drug: Bexagliflozin tablets, 20 mg; Bexagliflozin tablets, placebo and 1 more · For: Type2 Diabetes Mellitus
Sites: Birmingham, Alabama; Foley, Alabama; Little Rock, Arkansas · 43 sites in all
- Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal ImpairmentPivotal-lookingCompleted
TheracosIndustry
NCT02836873 · 312 participants · Start Sep 23, 2016 · Primary completion Jan 11, 2018
Drug: Bexagliflozin; Placebo · For: Type 2 Diabetes Mellitus
Sites: Fresno, California; La Palma, California; Lincoln, California · 56 sites in all
- A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes MellitusPivotal-lookingCompleted
TheracosIndustry
NCT02390050 · 292 participants · Start May 12, 2015 · Primary completion Jun 3, 2016
Drug: Bexagliflozin tablets; Bexagliflozin tablets, placebo · For: Diabetes Mellitus, Type 2
Sites: Peoria, Arizona; Tucson, Arizona; Canoga Park, California · 50 sites in all
- Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes MellitusPivotal-lookingCompleted
TheracosIndustry
NCT01377844 · 288 participants · Start Dec 2011 · Primary completion Nov 2013
Drug: EGT0001442; Placebo · For: Diabetes Mellitus
Sites: Buena Park, California; Los Angeles, California; Santa Ana, California · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache7
- weight decreased7
- fatigue6
- nausea6
- cough5
- decreased appetite5
- asthenia4
- chest discomfort4
- dyspnoea4
- gastrointestinal disorder4
- oropharyngeal pain4
- throat irritation4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 14 |
| 2026 | 10 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Allegretti AS, Zhang W, Zhou W, et al. · Am J Kidney Dis 2019 · Clinical Trial, Phase III, Multicenter Study
- Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials.
Guo J, Wei M, Zhang W, et al. · Front Pharmacol 2025 · Systematic Review
- Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Pasqualotto E, Figueiredo Watanabe JM, Gewehr DM, et al. · Diabetes Obes Metab 2023 · Meta-Analysis, Systematic Review
- Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Dholariya S, Dutta S, Singh R, et al. · Expert Opin Pharmacother 2023 · Meta-Analysis, Systematic Review
- Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials.
Gao S, Zhang F, Xie X, et al. · Front Endocrinol (Lausanne) 2026 · Network Meta-Analysis, Systematic Review
- Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials.
Lin M, Zhang S, Zhang L, et al. · Syst Rev 2025 · Meta-Analysis, Systematic Review
Sponsor: Theracosbio
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.